2024-09-15 - Analysis Report
## REGN Stock Analysis Report

**Company Overview:** Regeneron Pharmaceuticals, Inc. (REGN) is a biotechnology company that focuses on developing and commercializing life-transforming medicines for serious diseases.

**Performance Analysis:**

**1. Relative Performance:**

* **REGN Cumulative Return:** 155.01%
* **S&P 500 (VOO) Cumulative Return:** 87.74%
* **Outperformance:** 67.27% (93.08% relative to historical range)

REGN has significantly outperformed the S&P 500 over the period analyzed, with a relative outperformance exceeding 90% of historical observations.

**2. Recent Price Movement:**

* **Closing Price:** 1164.46
* **5-day Moving Average:** 1143.71
* **20-day Moving Average:** 1174.86
* **60-day Moving Average:** 1107.93

The stock is currently trading slightly below its 20-day moving average, suggesting potential short-term consolidation or a slight downward trend.

**3. Technical Indicators:**

* **RSI:** 43.05
* **PPO:** -0.7
* **Delta_Previous_Relative_Divergence:** -6.14 (Short-term downward trend)
* **Expected Return:** 5.23% (Max 5-year expected return for current invested amount)

The RSI suggests that REGN is currently in a neutral to slightly oversold territory. The PPO indicates a short-term bearish sentiment. The negative Delta_Previous_Relative_Divergence confirms the potential for a short-term pullback. However, the expected return remains positive, suggesting potential long-term growth.

**4. Recent Earnings and Outlook:**

| Date        | EPS  | Revenue |
|--------------|------|---------|
| 2024-08-01 | 13.25 | 3.55 B$  |
| 2024-05-02 | 6.7  | 3.15 B$  |
| 2023-11-02 | 9.48 | 3.36 B$  |
| 2023-08-03 | 9.05 | 3.16 B$  |
| 2024-08-01 | 9.05 | 3.16 B$  |

The most recent earnings report (2024-08-01) shows a significant EPS beat compared to expectations. Revenue also surpassed estimates, indicating strong performance. The consistent growth in both EPS and revenue over the past year reflects the company's robust performance and potential for future growth.

**Conclusion:**

REGN has exhibited strong historical performance, significantly outperforming the S&P 500. Recent earnings demonstrate positive growth and potential for continued success. However, short-term technical indicators suggest a potential pullback. Despite this, the expected return remains positive, indicating potential long-term growth. 

Overall, REGN appears to be a solid investment option with a favorable risk-reward profile. However, investors should closely monitor market conditions and technical indicators for short-term volatility. 
